Steba Biotech Completes its European Phase 3 Clinical Trial of TOOKAD® in Patients with Low-Risk Prostate Cancer and Submits Marketing Authorization Application to the European Medicine Agency

LUXEMBOURG, Jan. 25, 2016 /PRNewswire/ -- Steba Biotech, a privately owned biotechnology company focused on the development of innovative and minimally invasive photodynamic therapies and systems to treat cancers, today announced completion of PCM301, its European Phase 3 clinical trial of TOOKAD® (padeliporfin di-potassium), a novel investigational treatment for localized prostate cancer and other solid tumors. PCM301 is the first prospective randomized controlled trial evaluating the efficacy and safety of a focal therapy in prostate cancer. The data will be presented at the upcoming European Association of Urology scientific meeting in March.

Based on these results, Steba Biotech has submitted on January 7, 2016 a Marketing Authorization Application (MAA) to the European Medicine Agency (EMA) for TOOKAD®. The MAA requests EMA approval of TOOKAD® for the treatment of localized prostate cancer.

"With the completion of the PCM301 trial, our clinical experience with TOOKAD® now includes nearly 450 patients. We look forward to having the lead study investigator, Mark Emberton, M.D., share the full data at the upcoming European Association of Urology meeting," said Raphael Harari, Chief Executive Officer of Steba Biotech. "The submission of the MAA for TOOKAD® is a major milestone for Steba Biotech and we look forward to working closely with the EMA during the review period. If approved, TOOKAD® would provide physicians and patients with a unique innovative solution to manage low-risk prostate cancer."

Logo - []

About TOOKAD® (padeliporfin di-potassium)

TOOKAD® is a first-in-class photosensitizer derived from palladium-substituted bacteriochlorophyll and developed in collaboration with the Weizmann Institute. It was designed to address limitations of previous attempts in photodynamic therapies. Through its high solubility and activation with low energy, near-infrared light, TOOKAD® enables highly localized vascular occlusion that triggers targeted necrosis of tumor lesions, while sparing surrounding healthy tissue.

About PCM301 study design

The PCM301 study is a European, prospective, multicenter, open label, randomized, controlled study that compared TOOKAD® versus active surveillance. The study enrolled 413 low-risk prostate cancer patients (clinical stage up to cT2a, PSA10ng/mL in 3 consecutive measures, or any T3 stage prostate cancer, or any metastasis, or any prostate cancer-related death.

About low-risk prostate cancer

Low-risk prostate cancer (typically defined by clinical stage T1c-T2a, PSA

PR Newswire

Dit persbericht is via ANP Pers Support naar internationale (vak en online) media gestuurd. Heb je nieuws voor buitenlandse journalisten? Bekijk dan onze mogelijkheden of neem contact met ons op.

Verstuur nu éénmalig een persbericht

Verstuur persberichten en beeldmateriaal naar redacties in binnen- en buitenland. Via het ANP-net, het internationale medianetwerk van PR Newswire of met een perslijst op maat.

Direct persbericht versturen